Literature DB >> 7294765

Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects.

I Nilsson-Ehle, B Ursing, P Nilsson-Ehle.   

Abstract

We developed methods for measuring metronidazole, its two major metabolites, and tinidazole in serum and urine. After treatment of each sample with an equal volume of 5% perchloric acid, the drugs were separated by reverse-phase high-pressure liquid chromatography (retention times, 6 to 18 min). Quantitation was based on spectrometry at 320 nm. These assays were sensitive, rapid, and specific, and recoveries from biological samples were quantitative. Metronidazole and tinidazole were given as rapid intravenous infusions to four healthy human volunteers. The biological half-lives of these two compounds were 5.4 and 11.1 h, respectively. The hydroxy metabolite of metronidazole appeared quickly in serum and was eliminated at a slow rate. The acetic acid metabolite of metronidazole was detected in serum at very low levels and only for a limited time. No metabolic products of tinidazole were found in serum samples. In urine, 43.7% of the administered dose of metronidazole was recovered over a period of 24 h (24.1% of the dose as the hydroxy metabolite, 12.0% as the acetic acid metabolite, and 7.6% as unchanged drug). Only 18.4% of the infused dose of tinidazole was eliminated in urine over a period of 72 h, and no metabolic products were detected.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7294765      PMCID: PMC181517          DOI: 10.1128/AAC.19.5.754

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  GLC analysis of metronidazole in human plasma.

Authors:  N F Wood
Journal:  J Pharm Sci       Date:  1975-06       Impact factor: 3.534

2.  Antibiotic susceptibility testing of anaerobic bacteria by the standardized disc diffusion method with special reference to bacteroides fragilis.

Authors:  K Dornbusch; C E Nord; B Olsson
Journal:  Scand J Infect Dis       Date:  1975

3.  In vitro effect of metronidazole and tinidazole on anaerobic bacteria.

Authors:  K Dornbusch; C E Nord
Journal:  Med Microbiol Immunol       Date:  1974       Impact factor: 3.402

4.  Pharmacokinetics of metronidazole as determined by bioassay.

Authors:  E D Ralph; J T Clarke; R D Libke; R P Luthy; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

5.  Microbiological agar diffusion assay for metronidazole concentrations in serum.

Authors:  M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

6.  The pharmacokinetics of metronidazole and tinidazole in man.

Authors:  P G Welling; A M Monro
Journal:  Arzneimittelforschung       Date:  1972-12

7.  Determination of therapeutic levels of metronidazole in plasma by gas-liquid chromatography.

Authors:  K K Midha; I J McGilveray; J K Cooper
Journal:  J Chromatogr       Date:  1973-12-19

8.  The isolation and identification of the urinary oxidative metabolites of metronidazole in man.

Authors:  J E Stambaugh; L G Feo; R W Manthei
Journal:  J Pharmacol Exp Ther       Date:  1968-06       Impact factor: 4.030

9.  Treatment of anaerobic infections with metronidazole.

Authors:  F P Tally; V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

10.  Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose.

Authors:  G W Houghton; P S Thorne; J Smith; R Templeton; J Collier
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

View more
  15 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Authors:  Robin E Pearce; Michael Cohen-Wolkowiez; Mario R Sampson; Gregory L Kearns
Journal:  Drug Metab Dispos       Date:  2013-06-27       Impact factor: 3.922

Review 3.  Clinical pharmacokinetics of metronidazole.

Authors:  E D Ralph
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

4.  Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria.

Authors:  J P O'Keefe; K A Troc; K D Thompson
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

Review 5.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

6.  Behavior of antibiotics during human necrotizing pancreatitis.

Authors:  C Bassi; P Pederzoli; S Vesentini; M Falconi; A Bonora; H Abbas; A Benini; E M Bertazzoni
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.

Authors:  B L Flouvat; C Imbert; D M Dubois; B P Temperville; A F Roux; G C Chevalier; G Humbert
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

Review 8.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

9.  Tinidazole pharmacokinetics in severe renal failure.

Authors:  R A Robson; R R Bailey; J R Sharman
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.